[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer
J Clore, PJH Scott - Expert Review of Molecular Diagnostics, 2024 - Taylor & Francis
Introduction Theranostics targeting prostate-specific membrane antigen (PSMA) represent a
new targeted approach for prostate cancer care that combines diagnostic and therapeutic …
new targeted approach for prostate cancer care that combines diagnostic and therapeutic …
PSMA-targeted radiopharmaceuticals for prostate cancer diagnosis and therapy
JD Oldan, F Almaguel, AF Voter, A Duran… - The Cancer …, 2024 - journals.lww.com
Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
The first-in-human preclinical evaluation of the new probe [123I] I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT/CT imaging in prostate cancer
X Luan, S Niu, Y Liu, X Zhang, X Xu, S Sun… - European Journal of …, 2024 - Springer
Purpose PSMA/PET has been increasingly used to detect PCa, and PSMA/PET-guided
biopsy has shown promising results. However, it cannot be confirmed immediately whether …
biopsy has shown promising results. However, it cannot be confirmed immediately whether …
Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging …
P Kanellopoulos, E Bezverkhniaia, A Abouzayed… - ACS …, 2024 - ACS Publications
Gastrin releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PC-3) and
can be used for diagnostic purposes. We herein present the design and preclinical …
can be used for diagnostic purposes. We herein present the design and preclinical …
[HTML][HTML] Clinical, diagnostic and therapeutic framework of mHSPC and nmCRPC: a multidisciplinary consensus project of the Italian Society for Uro-Oncology (SIUrO)
RM D'Angelillo, O Caffo, N Borsellino… - Clinical Genitourinary …, 2024 - Elsevier
The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC)
and in non-metastatic castration resistant (nmCRPC) introduced the possibility to adopt …
and in non-metastatic castration resistant (nmCRPC) introduced the possibility to adopt …
Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation
Rationale and Objectives To determine whether concurrent contrast-enhanced diagnostic
CT (DxCT) confers added diagnostic certainty compared to PSMA-PET/CT alone. Materials …
CT (DxCT) confers added diagnostic certainty compared to PSMA-PET/CT alone. Materials …